Navigation Links
Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
Date:2/7/2008

WALTHAM, Mass., Feb. 7 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today that its co-founder and CEO Mitchell P. Fink M.D. was presented with the Distinguished Investigator Award from the American College of Critical Care Medicine during the 37th Critical Care Congress of the Society of Critical Care Medicine held February 2-6 in Honolulu, Hawaii.

The prestigious recognition was awarded to Dr. Fink for his pioneering research related to the pathogenesis and treatment of sepsis, a serious medical condition characterized by widespread inflammation, due to infection.

Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh, the first such department at a medical school in the United States. Dr Fink also held other University appointments including Professor of Pharmacology, the Watson Professor of Surgery, and Associate Vice-chancellor for Translational Research. Dr. Fink's academic research program was continuously funded by the National Institutes of Health for more than 20 years.

The Society of Critical Care Medicine, which bestowed the honor to Dr. Fink, is the leading professional organization dedicated to ensuring excellence and consistency in the practice of critical care medicine. With more than 13,000 members worldwide, the Society is the only professional organization devoted exclusively to the advancement of multi-professional intensive care through excellence in patient care, professional education, public education, research and advocacy.

Dr. Fink is an author or co-author of more than 250 peer-reviewed scientific publications, has edited or co-edited 13 textbooks and is currently an Associate Editor for two highly regarded scientific journals: the Journal of Pharmacology and Experimental Therapeutics and the Journal of Leukocyte Biology.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. For more information on Logical Therapeutics, visit the company's website at http://www.logicaltherapeutics.com or by email at info@logicaltherapeutics.com


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Montana State University lab gives early warnings about biological invaders
4. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
5. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
10. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
11. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... share findings demonstrating the value of DNA microarray comparative genomic hybridization (array ... San Antonio Breast Cancer Symposium. Using molecular test results from tumors with ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the ... will take place on February 1-3, 2017 at the Roosevelt Hotel in New York ... program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control technologies ... portable online UHPLC, with robust, probe-based sampling. , Online liquid chromatography ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
Breaking Biology Technology:
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/15/2016)... Research and Markets has announced the addition ... report to their offering. ... The global ... from USD 6.21 Billion in 2016, growing at a CAGR of ... bioinformatics market is driven by the growing demand for nucleic acid ...
Breaking Biology News(10 mins):